The CYP/20-HETE/GPR75 axis in hypertension

Area of Science:

• Biochemistry
• Cardiovascular Physiology
• Pharmacology

Background:

• 20-Hydroxyeicosatetraenoic acid (20-HETE) is a lipid mediator derived from arachidonic acid (AA) via cytochrome P450 (CYP) enzymes.
• 20-HETE significantly influences vascular tone, renal function, and is implicated in hypertension and cardiovascular disease development.
• Its pro-hypertensive effects involve vascular sensitization, endothelial dysfunction, and inflammation, mediated by the G-protein coupled receptor 75 (GPR75), also known as the 20-HETE receptor (20HR).

Purpose of the Study:

• To review the cellular mechanisms by which 20-HETE signaling contributes to hypertension.
• To highlight human genetic data related to CYP gene variants and 20HR/GPR75 mutations affecting 20-HETE production and signaling.
• To emphasize the therapeutic potential of targeting the CYP/20-HETE/GPR75 axis for hypertension and related conditions.

Main Methods:

• Literature review of cellular mechanisms.
• Analysis of human genetic studies on CYP and GPR75 variants.
• Review of preclinical and clinical data on 20HR/GPR75 blockers.

Main Results:

• 20-HETE signaling pathways activate GPR75, leading to pro-hypertensive effects.
• Genetic variations in CYP genes can increase 20-HETE production, correlating with hypertension.
• Mutations in 20HR/GPR75 are observed in humans, providing insights into receptor function.
• 20HR blockers show promise in preclinical models for treating 20-HETE-driven hypertension.

Conclusions:

• The CYP/20-HETE/GPR75 axis is a critical pathway in the pathogenesis of hypertension.
• Targeting 20-HETE signaling, particularly through GPR75 antagonism, represents a promising therapeutic avenue.
• Further translational and clinical studies are warranted for 20-HETE-targeted therapies for hypertension, obesity, and metabolic syndrome.